Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Processa Pharmaceuticals, Inc.PCSA · Entity 8210 | Chief Business - Strategy Off | July 26, 2026 | July 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Processa Pharmaceuticals, Inc.
Report date July 26, 2026 · Filed July 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 11,389 |
Reported balance
After 2026-07-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-26 · Grant · Acquired 8,450 · Balance 11,389 F1: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F3: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 13,113 |
Reported balance
Holding disclosure · report date 2026-07-26 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 13,113 |
| Common StockSEC Table I · non-derivative | IndirectLin Family Trust Feb 4, 2024 | 1,740 |
Reported balance
Holding disclosure · report date 2026-07-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,740 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.96 | Direct | 8,160 |
Reported balance
Holding disclosure · report date 2026-07-26 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 8,160 F2: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years. F3: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.
F2: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.
F3: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 26, 2026 Filed Jul 29, 2026 00:23 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 8,450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-26-001550 · form4.xml · derivative · entry 3 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,389 Underlying: Common Stock · 8,450 shares Expires not disclosed F1 · shares: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death. F3 · balance_after: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:19 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 2,106 | $1.93 | $4,064.58 |
DisclosureSEC source: 0000897069-26-001482 · form4.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,113 Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 20:21 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 1,831 | $2.22 | $4,064.82 |
DisclosureSEC source: 0000897069-26-001408 · form4.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,007 Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 20:56 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 1,582 | $2.57 | $4,065.74 |
DisclosureSEC source: 0000897069-26-001289 · form4.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,176 Read SEC document |
| May 15, 2026 Filed May 19, 2026 22:02 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 1,369 | $2.97 | $4,065.93 |
DisclosureSEC source: 0000897069-26-001182 · form4.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,594 F1 · balance_after: Shares adjusted to correct immaterial errors made on the Form 4 filed on May 1, 2026. The corrected price per share for the purchase made on April 30, 2026 is $2.71, not $2.69, which reduces the amount purchased on April 30, 2026 by 11 shares. Read SEC document |
| April 30, 2026 Filed May 1, 2026 20:36 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 1,511 | $2.69 | $4,064.59 |
DisclosureSEC source: 0000897069-26-001004 · form4.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,236 Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:52 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 1,369 | $2.97 | $4,065.93 |
DisclosureSEC source: 0000897069-26-000908 · form4.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,725 Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:11 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 1,603 | $2.54 | $4,063.61 |
DisclosureSEC source: 0000897069-26-000747 · form4.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,356 Read SEC document |
| January 01, 2026 Filed Feb 4, 2026 22:07 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock · Derivative | 193 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-26-000222 · form4.xml · derivative · entry 3 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 193 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Distribution of vested restricted shares. F1 · derivative.expiration_date: Distribution of vested restricted shares. Read SEC document |
| January 01, 2026 Filed Feb 4, 2026 22:07 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 193 | $0.00 | $0.00 |
DisclosureSEC source: 0000897069-26-000222 · form4.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:31 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantStock Options (Right to Buy) · Derivative | 204,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0000897069-25-001551 · form4.xml · derivative · entry 2 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,000 Underlying: Common Stock · 204,000 shares Expires not disclosed F2 · derivative.exercise_date: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years. F2 · derivative.expiration_date: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:31 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 68,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-25-001551 · form4.xml · derivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,000 Underlying: Common Stock · 68,000 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028. Read SEC document |
| July 24, 2025 Filed Jul 28, 2025 20:34 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 1,401,650 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-25-001221 · form4.xml · derivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,412,082 Underlying: Common Stock · 1,401,650 shares Expires not disclosed F1 · shares: Restricted stock granted under the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan ("Omnibus Plan"), of which 1,384,411 shares are subject to stockholder approval of the revised Omnibus Plan. F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028. Read SEC document |
| April 01, 2025 Filed Apr 11, 2025 21:22 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 4,814 | $0.41 | $1,983.37 |
DisclosureSEC source: 0000897069-25-000795 · form4.xml · nonDerivative · entry 2 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,727 Read SEC document |
| April 01, 2025 Filed Apr 11, 2025 21:22 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 14,482 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-25-000795 · form4.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares Read SEC document |
| January 29, 2025 Filed Feb 18, 2025 22:54 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantWarrants · Derivative | 21,750 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0000897069-25-000292 · form4.xml · derivative · entry 4 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Indirect · Lin Family Trust Feb 4, 2024 Disclosed balance after: 21,750 Underlying: Common Stock · 21,750 shares Expires 2030-01-29 Read SEC document |
| January 29, 2025 Filed Feb 18, 2025 22:54 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantWarrants · Derivative | 43,500 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0000897069-25-000292 · form4.xml · derivative · entry 3 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Indirect · Lin Family Trust Feb 4, 2024 Disclosed balance after: 43,500 Underlying: Common Stock · 43,500 shares Expires 2030-01-29 Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:20 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 43,500 | $0.80 | $34,691.25 |
DisclosureSEC source: 0000897069-25-000130 · form4.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Indirect · Lin Family Trust Feb 4, 2024 Disclosed balance after: 43,500 Read SEC document |
| July 10, 2024 Filed Aug 2, 2024 21:28 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 271 | $1.71 | $463.41 |
DisclosureSEC source: 0000897069-24-001611 · form4.xml · nonDerivative · entry 4 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,059 Read SEC document |
| July 10, 2024 Filed Aug 2, 2024 21:28 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 644 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-001611 · form4.xml · nonDerivative · entry 3 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 21:28 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 339 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001611 · form4.xml · derivative · entry 8 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,914 Underlying: Common Stock · 339 shares Expires not disclosed F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 21:28 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 339 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001611 · form4.xml · derivative · entry 7 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,575 Underlying: Common Stock · 339 shares Expires not disclosed F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 21:28 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 2,035 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001611 · form4.xml · derivative · entry 6 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,236 Underlying: Common Stock · 2,035 shares Expires not disclosed F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 21:28 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 2,713 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001611 · form4.xml · derivative · entry 5 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,201 Underlying: Common Stock · 2,713 shares Expires not disclosed F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025. Read SEC document |
| April 05, 2024 Filed Aug 2, 2024 21:28 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 539 | $2.79 | $1,503.81 |
DisclosureSEC source: 0000897069-24-001611 · form4.xml · nonDerivative · entry 2 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,686 Read SEC document |
| April 05, 2024 Filed Aug 2, 2024 21:28 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 1,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-001611 · form4.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. Read SEC document |
| February 01, 2024 Filed Feb 1, 2024 23:32 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 1,500 | $2.40 | $3,600.00 |
DisclosureSEC source: 0000897069-24-000236 · form4.xml · nonDerivative · entry 2 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,478 F1 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 23:32 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 2,500 | $2.37 | $5,925.00 |
DisclosureSEC source: 0000897069-24-000236 · form4.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,978 F1 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 20:55 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionRestricted Stock Units · Derivative | 1,675 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-000921 · form4.xml · derivative · entry 3 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,132 Underlying: Common Stock · 1,675 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Distribution of vested restricted shares. F1 · derivative.expiration_date: Distribution of vested restricted shares. F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 20:55 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 539 | $2.79 | $1,503.81 |
DisclosureSEC source: 0000897069-24-000921 · form4.xml · nonDerivative · entry 2 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,614 F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 20:55 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 1,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-000921 · form4.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| October 12, 2023 Filed Oct 12, 2023 22:01 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 5,000 | $0.32 | $1,600.00 |
DisclosureSEC source: 0000897069-23-001466 · form4.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 469,535 Read SEC document |
| October 10, 2023 Filed Oct 10, 2023 21:00 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 13,700 | $0.21 | $2,877.00 |
DisclosureSEC source: 0000897069-23-001442 · form4.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 464,535 Read SEC document |
| February 09, 2023 Filed Feb 10, 2023 22:09 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 12,500 | $0.80 | $10,000.00 |
DisclosureSEC source: 0001567619-23-002400 · doc1.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,835 Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 22:46 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 40,690 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000327 · doc1.xml · derivative · entry 3 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,328 Underlying: Common Stock · 40,690 shares Expires not disclosed F3 · derivative.exercise_date: Each restricted stock units represents a contingent right to receive one share of the lssuers common stock, following its vesting of one-third on 01/01/24; 01/01/25 and 01/01/26, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death. F3 · derivative.expiration_date: Each restricted stock units represents a contingent right to receive one share of the lssuers common stock, following its vesting of one-third on 01/01/24; 01/01/25 and 01/01/26, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 22:46 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 55,107 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000327 · doc1.xml · derivative · entry 2 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,638 Underlying: Common Stock · 55,107 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock units represents a contingent right to receive one share of the lssuers common stock, following its vesting on 01/01/24, upon the earlier of termination of employment; the third anniversary of the award date;a change in control, orthe reporting persons death, F2 · derivative.expiration_date: Each restricted stock units represents a contingent right to receive one share of the lssuers common stock, following its vesting on 01/01/24, upon the earlier of termination of employment; the third anniversary of the award date;a change in control, orthe reporting persons death, Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 22:46 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 10,851 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000327 · doc1.xml · derivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,531 Underlying: Common Stock · 10,851 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. These restricted stock units vest on date of grant. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. These restricted stock units vest on date of grant. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 20:52 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 10,850 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-018058 · doc1.xml · derivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,680 Underlying: Common Stock · 10,850 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 20:22 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 2,656 | $3.17 | $8,419.52 |
DisclosureSEC source: 0001567619-22-015301 · doc1.xml · nonDerivative · entry 2 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 438,335 Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 20:22 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 7,601 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-015301 · doc1.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Vesting of time-based shares. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 21:37 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 20,064 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-013683 · doc1.xml · derivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,830 Underlying: Common Stock · 20,064 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| May 17, 2022 Filed May 19, 2022 22:11 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 2,000 | $1.59 | $3,189.00 |
DisclosureSEC source: 0001567619-22-011300 · doc1.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 433,390 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.53 to $1.77, inclusive. The Reporting Person undertakes to provide, Processa Pharmaceuticals, Inc. (the "Company") any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| April 07, 2022 Filed Apr 8, 2022 20:49 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 800 | $3.54 | $2,835.04 |
DisclosureSEC source: 0001567619-22-008312 · doc1.xml · nonDerivative · entry 2 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,390 F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.45 to $3.60, inclusive. The Reporting Person undertakes to provide, Processa Pharmaceuticals, Inc. (the "Company") any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 20:49 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 1,200 | $3.13 | $3,752.04 |
DisclosureSEC source: 0001567619-22-008312 · doc1.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,590 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.10 to $3.18, inclusive. The Reporting Person undertakes to provide, Processa Pharmaceuticals, Inc. (the "Company") any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| April 01, 2022 Filed Apr 11, 2022 21:51 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 247,841 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-008363 · doc1.xml · derivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,766 Underlying: Common Stock · 247,841 shares Expires not disclosed F1 · derivative.exercise_date: Restricted Stock Units (RSUs) vest upon achievement of certain performance goals. The grant of 136,632 RSUs are subject to shareholder approval of the Issuer's 2019 Omnibus Incentive Plan (the "Plan") to increase the authorized shares under the Plan. F1 · derivative.expiration_date: Restricted Stock Units (RSUs) vest upon achievement of certain performance goals. The grant of 136,632 RSUs are subject to shareholder approval of the Issuer's 2019 Omnibus Incentive Plan (the "Plan") to increase the authorized shares under the Plan. F2 · balance_after: The previous filing understated this number. This new total accurately reflects the cumulative total of Restricted Stock Units for the reporting person. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:48 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 10,715 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-007987 · doc1.xml · derivative · entry 2 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,781 Underlying: Common Stock · 10,715 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| December 31, 2021 Filed Jan 6, 2022 22:23 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 6,722 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000770 · doc1.xml · derivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,780 Underlying: Common Stock · 6,722 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F2 · balance_after: This Amendment is being filed to correct the balance in Box 9 - this should have reflected a cumulative balance. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 21:37 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 3,000 | $4.00 | $12,000.00 |
DisclosureSEC source: 0001567619-21-022195 · doc1.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,390 Read SEC document |
| December 14, 2021 Filed Jan 4, 2022 22:26 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 3,000 | $4.00 | $12,000.00 |
DisclosureSEC source: 0001567619-22-000291 · doc1.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,390 Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 21:33 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 3,500 | $4.80 | $16,795.10 |
DisclosureSEC source: 0001567619-21-021708 · doc1.xml · nonDerivative · entry 1 Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,390 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.79 to $4.85, inclusive. The Reporting Person undertakes to provide, Processa Pharmaceuticals, Inc. (the "Company") any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.